Published in Blood Weekly, March 9th, 2006
Study 1: Four consecutive Pediatric Oncology Group (POG) clinical trials for childhood acute myeloid leukemia (AML) were reviewed.
"From 1981 to 2000, a total of 1823 children with AML enrolled on four consecutive POG clinical trials. POG 8101 demonstrated that the induction rate associated with the 3 + 7 + 7 combination of daunorubicin, Ara-C, and 6-thioguanine (DAT) was greater than that associated with an induction regimen used to treat acute lymphoblastic leukemia (82 vs 61%; p=.02)," researchers in the United States reported.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.